US2020138729A1PendingUtilityA1

Implantable drug delivery compositions and methods of use thereof

57
Assignee: ACUITYBIO CORPPriority: Jun 18, 2015Filed: Nov 11, 2019Published: May 7, 2020
Est. expiryJun 18, 2035(~8.9 yrs left)· nominal 20-yr term from priority
Inventors:John SchwartzAaron Henry Colby
A61L 2300/602A61L 27/56A61L 2300/802A61L 27/58A61K 9/0024A61K 31/337A61L 31/148A61L 27/16A61L 27/34A61L 31/10A61K 47/10A61L 27/18A61K 9/70A61L 27/54A61L 31/16A61K 47/46A61P 35/00A61L 2300/416A61L 31/06A61L 27/24A61L 2300/404A61K 9/007A61K 47/34A61K 9/5021A61L 27/3604A61K 47/30A61K 31/16A61K 31/14A61K 31/10A61K 9/00A61K 9/16A61K 9/7007
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein are implantable compositions and methods of use thereof for the local delivery of therapeutically active agents.

Claims

exact text as granted — not AI-modified
1 . An implantable composition comprising a matrix together with at least one polymer and a therapeutically active agent. 
     
     
         2 . The implantable composition of  claim 1 , further comprising at least one excipient. 
     
     
         3 . The implantable composition of  claim 1 , wherein the at least one polymer, at least one excipient, and therapeutically active agent are separate and distinct entities. 
     
     
         4 . The implantable composition of  claim 2 , wherein the at least one polymer, therapeutically active agent, and at least one excipient are embedded in the matrix, coated on the matrix, embedded in and coated on the matrix, or covalently linked to the matrix. 
     
     
         5 . The implantable composition of  claim 1 , wherein the matrix comprises a membrane or porous scaffold. 
     
     
         6 . The implantable composition of  claim 1 , wherein the matrix is a non-woven polymer mesh. 
     
     
         7 . The implantable composition of  claim 1 , wherein the matrix is a woven polymer mesh. 
     
     
         8 . The implantable composition of  claim 1 , wherein the matrix is a biological matrix. 
     
     
         9 . The implantable composition of  claim 1 , wherein the matrix is a biological matrix selected from collagen sheets, bovine pericardium, human or animal dura or the like. 
     
     
         10 . The implantable composition of  claim 1 , wherein the matrix is a polymer matrix comprising one or more of poly(ethylene), poly(propylene), poly(tetrafluroethylene), poly(methymethacrylate), ethylene-co-vinylacetate, poly(dimethylsiloxane), poly(ether-urethanes), polycarbonate, polyethersulphone, polybenzimidazole, acrylonitrile butadiene styrene (ABS), polyvinyl chloride (PVC), polyether ether ketone (PEEK), poly(ethylene terphthalate), poly(sulphone), poly(esters) based on polylactide (PLA), polyglycolide (PGA), polycaprolactone (PCL), poly(hydroxyalkanoate)s, poly(saccharide)s, their copolymers and blends or combinations of copolymers and blends. 
     
     
         11 . The implantable composition of  claim 1 , wherein the matrix is a polymer matrix comprising polyglycolic acid (PGA). 
     
     
         12 . The implantable composition of  claim 3 , wherein the therapeutically active agent comprises about 50% by weight or less, or about 25% by weight or less of the total weight of the at least one polymer and at least one excipient embedded in the matrix, coated on the matrix, or embedded in and coated on the matrix. 
     
     
         13 . The implantable composition of  claim 3 , wherein the therapeutically active agent comprises about 20% by weight or less of the total weight of the at least one polymer and at least one excipient embedded in the matrix, coated on the matrix, or embedded in and coated on the matrix. 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . The implantable composition of  claim 3 , wherein the excipient comprises about 50% by weight or less of the total weight of the at least one polymer and therapeutically active agent embedded in the matrix, coated on the matrix, or embedded in and coated on the matrix. 
     
     
         17 - 19 . (canceled) 
     
     
         20 . The implantable composition of  claim 1 , wherein the therapeutically active agent is selected from an antifungal, an anti-infective antineoplastic, an anti-viral, an analgesic, a nonsteroidal anti-inflammatory drug, a narcotic, an alzheimer's agent, an anticancer agent an androgenic agent, an angiotensin modulator, an anticoagulant, a anticonvulsant, an antidepressant, an anti-Parkinson's agent, a antipsychotic, a antianginal, a beta and alpha blocker, a bone resorption suppression and related agent, a BPH agent, a bronchodialator anticholinergic and beta antagonist agent, a calcium channel blocker, a cytokine and CAM antagonist, a glucocorticoid, a hormone, a hepatitis treatment agent, a leukotriene modifier, a multiple sclerosis agent, a opthalmic glaucoma agent, and a pulmonary antihypertensive-endothelin receptor antagonist. 
     
     
         21 . The implantable composition of  claim 1 , wherein the therapeutically active agent is an anticancer agent. 
     
     
         22 . (canceled) 
     
     
         23 . (canceled) 
     
     
         24 . The implantable composition of  claim 1 , wherein the therapeutically active agent is paclitaxel. 
     
     
         25 . The implantable composition of  claim 1 , wherein the therapeutically active agent is paclitaxel in an amount ranging from 10 ug/cm 2  and 450 ug/cm 2 , about 150 ug/cm 2  and about 300 ug/cm 2 , or about 225 ug/cm 2  and about 275 ug/cm 2 . 
     
     
         26 . (canceled) 
     
     
         27 . The implantable composition of  claim 2 , wherein the at least one excipient is selected from polyvinyl pyrrolidone (PVP), polyethylene oxide (PEO), polyvinyl alcohol (PVA), hydroxypropyl cellulose (HPC), hydroxypropylmethylcellulose acetate succinate (HPMCAS), ethylene vinyl acetate (EVA), methacrylates, ethyl cellulose (EC), cellulose acetate butyrate (CAB), cellulose acetate phthalate (CAP), polyethylene glycol, polyvinyl acetate (PVAc), polylactide (PLA), polyglycolide (PGA), copolymers of PLA/PGA and polycaprolactone (PCL), polyvinylpyrrolidone-co-vinyl acetate, and polyurethanes. 
     
     
         28 . (canceled) 
     
     
         29 . The implantable composition of  claim 2 , wherein the at least one excipient is polyethylene glycol having a molecular weight greater than about 1,000 g/mol. 
     
     
         30 - 32 . (canceled) 
     
     
         33 . The implantable composition of  claim 2 , wherein the at least one excipient is polyethylene glycol 8000. 
     
     
         34 . The implantable composition of  claim 1 , wherein the at least one polymer is poly(lactic-co-glycolic acid) copolymer (PGLA). 
     
     
         35 . The implantable composition of  claim 1 , wherein the at least one polymer is poly(lactic-co-glycolic acid) copolymer (PGLA) having a lactide/glycolide molar ratio of about 20:80, about 25:75, about 40:60, about 45:55, about 53:47, about 55:45, about 50:50, about 60:40, about 75:25, or about 80:20. 
     
     
         36 . (canceled) 
     
     
         37 . The implantable composition of  claim 1 , wherein the at least one polymer is poly(lactic-co-glycolic acid) copolymer (PGLA) having a molecular weight ranging from about 20,000 g/mol to about 250,000 g/mol, about 50,000 g/mol to about 150,000 g/mol, about 65,000 g/mol to about 100,000 g/mol, or about 70,000 g/mol to about 80,000 g/mol. 
     
     
         38 - 41 . (canceled) 
     
     
         42 . A method of reducing the risk of acquiring a cancer in a subject in need thereof comprising surgically affixing the implantable composition of  claim 1  in or on the subject. 
     
     
         43 - 53 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.